Development of an antiseizure drug screening platform for Dravet syndrome at the NINDS contract site for the Epilepsy Therapy Screening Program

OBJECTIVE: Dravet syndrome (DS) is a rare but catastrophic genetic epilepsy, with 80% of patients carrying a mutation in the SCN1A gene. Currently, no antiseizure drug (ASD) exists that adequately controls seizures. In the clinic, individuals with DS often present first with a febrile seizure and, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Pernici, Chelsea D., Mensah, Jeffrey A., Dahle, E. Jill, Johnson, Kristina J., Handy, Laura, Buxton, Lauren, Smith, Misty D., West, Peter J., Metcalf, Cameron S., Wilcox, Karen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8360068/
https://www.ncbi.nlm.nih.gov/pubmed/34002394
http://dx.doi.org/10.1111/epi.16925

Ejemplares similares

Ejemplares similares